Success Stories: Ph.D. Candidate from Russia Specializing in Molecular Biology with Approved NIW Obtained EAD and AP After Filing I-485

Client’s Testimonial:

“Thank you very much again for all the work you did for my I-140! I’m very happy it was approved! I’ll definitely be recommending your firm to all my friends who consider filing their own immigration petitions.”

On September 30^th, 2019, we received another EB-2 NIW (National Interest Waiver) approval for a PhD Candidate in the Field of Molecular Biology (Approval Notice).

General Field: Molecular Biology

Position at the Time of Case Filing: PhD Candidate

Country of Origin: Russia

State of Residence at the Time of Filing: New York

Approval Notice Date: September 30^th, 2019

Processing Time: 5 months, 26 days

Case Summary:

Less than 6 months after North America Immigration Law Group (WeGreened.com) filed an I-140 EB-2 NIW (National Interest Waiver) petition for a Russian PhD candidate, the USCIS granted him case approval. With a M.D. and extensive experience in molecular biology, our client met the National Interest Waiver requirements set by Matter of Dhanasar.

We applied our firm’s vast experience to our client’s case and highlighted his work on identifying therapeutics targeting the molecular mechanisms of several serious health concerns, including cancer, kidney disease, and neurodegenerative disorders. The benefits offered by gene therapy is vital to treating genetic diseases that were previously difficult or impossible to cure, thus making our client’s research valuable to public health and clinical medicine around the world. In fact, he has communicated the findings of his extensive studies through impressive 10 peer-reviewed journal articles, and the significance of his publications is distinct based on the 74 times his work were cited and the 35 instances of peer reviews he performed.

Moreover, we made sure to incorporate letters of recommendation signed by notable experts in the field who are well-positioned to discuss the importance of our client’s influential projects within molecular biology research and how his work sustained national and international acclaim. Statements contained in two such letters confirmed our arguments:

“Lung cancer is the second most prevalent type of cancer in the United States today and the leading cause of cancer-related deaths…[Client] is a leading molecular biologist whose work has been integral in addressing this issue, and his research provides benefits to a major sector within the U.S. and helps improve the public health of its citizens”.

“This study provided critical insights into the influence of a compound’s chemical structure on its biological activities, an immensely valuable contribution to therapeutics research, and is just one example of the quality and creativity of [Client]’s work.”

Concurrent Filing of I-140 and I-485:

Applicants applying for their green card in the US have three options if their priority date is current: they can file an I-485 application after their I-140 is approved, file the I-485 while the I-140 is pending approval, or file them simultaneously. In this case, our client chose the third option to file his NIW petition and I-485 concurrently. There are several benefits to concurrent filing, one of which gives the USCIS a head start in processing his I-485 application. Additionally, he obtained his Employment Authorization Documents (EAD) and Advance Parole (AP) after filing I-765 and I-131 applications based on his I-485.

To find out more about Concurrent Filing of I-140 and I-485, please head to:
http://www.wegreened.com/I-140-and-I-485-concurrent-filing

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.